


Strengthening the UK environment for clinical research - progress

UK-wide compatibility

- UK Local Information Pack site set-up
- Organisation Information Document template



5 June 2019



<http://www.nhsresearchscotland.org.uk/services/uk-wide-working>

Non-commercial research

Scotland / NI




SSI

England / Wales




Statement
of
Activities

Non-commercial research



Non-commercial research



Commercial research

Scotland / NI




SSI

England / Wales




Sponsor
email/
letter

Commercial research




Commercial research



Strengthening the UK environment for clinical research: Progress

- Working towards single contract review for commercial research from April 2019
- Implementing new national model for excess treatment costs in non-commercial research




National Directive on Commercial Clinical Research Studies

If the Provider chooses to participate in any Commercial Contract Research Study which is submitted to the HRA for approval on or after 1 October 2018, the Provider must ensure that that participation will be in accordance with the National Directive on Commercial Contract Research Studies, at a price determined by NIHR for each Provider in accordance with the methodology prescribed in the Directive and under such other contractual terms and conditions as are set out in the Directive.


Before



Negotiate
resource
requirements at
multiple sites



Validate locally
per site



Variation in
resource at
different sites


After



Define resource
requirements at
lead site



Validate by
Clinical
Research
Network



Apply at other
sites

Benefits

- National standards for defining resource requirements
- Consistent approach to site costing
- Enable earlier 'site open' dates by minimising the time negotiating costs and contracts at individual sites

www.supportmystudy.nihr.ac.uk

NHS

Health Research
Authority

NHS **70**
England YEARS
OF SERVICE

NHS England's response to the public consultation:


"Supporting Research in the NHS: A consultation covering changes to simplify arrangements for research in the NHS and associated changes to the terms of the NHS Standard Contract"

NHS **NHS** **NHS**
Improvement Health Research Authority National Institute for Health Research

Strengthening the UK environment for research - next steps


Strengthening the UK environment for clinical research: next steps

- Establish five purpose-designed centres dedicated to late-phase commercial research
- Address challenges in NHS workforce resourcing to deliver commercial research
- Exploring opportunities to incentivise NHS Trusts and GP practices to act as participant identification centres (PICs)




Strengthening the UK environment for clinical research: next steps

- Promote expertise in designing innovative trials
- Develop expertise in delivering innovative studies in the NHS



Strengthening the UK environment for clinical research: next steps


- Investment in the infrastructure needed to support the expansion of digitally-enabled clinical research
- Creation and linkage of national data systems to support rapid, efficient trials



Strengthening the UK environment for research - how are we doing?


HRA Approval Performance

Calendar days including applicant response




NHS Long Term Plan

- Recognises the critical importance of research and innovation to drive future medical advance



UK in a Global Setting

Data source: Global CRO



Already implemented

- HRA/ HCRW Approval – England and Wales
- UK-wide IRAS Form
- E-submission to MHRA for medical devices
- Technical Assurances

Radiation Assurance

- Open to cardiology, oncology, neurology and rheumatology studies
- Coordinates lead Clinical Radiation Expert (CRE) and lead Medical Physics Expert (MPE) reviews in IRAS

<https://www.hra.nhs.uk/approvals-amendments/what-approvals-do-i-need/technical-assurances/radiation-assurance/>

Pharmacy Assurance


- Open to oncology phase I to III
- Clear information for sites
- Reduces queries from sites to sponsor
- Reduces duplication at sites – to reduce delays

Pharmacy manual is not mandatory!

<https://www.hra.nhs.uk/approvals-amendments/what-approvals-do-i-need/technical-assurances/pharmacy-assurance/>

What can you do?

Applications with missing documents



What are we seeing?

- Missing contracts and costings
- Copy/paste answers in IRAS not reflecting the study
- Contradiction between documents
- No IRAS ID on PIS
- Unclear on information governance
- Unclear on tissue handling
- Unclear on contracts and modifications
- Costing template not validated by CRN

Queries raised in REC meeting

- Detail on recruitment strategy – including approach
- Which tests are standard and which additional
- Justification on inclusion of adults lacking consent
- Is access to medical records necessary
- What support for participants in distress or anxious

Requests raised in REC letter

- Clarity on study procedures – expectations
- Will (and how) findings be fed back to participants
- How is the research different from standard care
- General risks and burdens to the participant should be made explicit
- Travel/expense reimbursement provided
- Complaints procedure
- Written in lay language

Issues with industry PIS

- Handling of clinically significant findings
- No distress policy
- Not clear how the substance has previously been used
- Side-effects frequency is not clear
- Summary information sheets have not been produced
- No information on alternatives
- No information about *relative* risk and benefit. How does the risk profile of the research option compare with that of the alternative available treatment (or no treatment) options?

Sign up to HRA Latest –

HRA Latest

October 2017

Follow the link at
www.hra.nhs.uk

Contents

New framework for UK health and social care research launched

Our joint statement on GCP training is published

New EU General Data Protection Regulation update is published

We want your feedback on the new HRA website

Preparing the UK for the EU Clinical Trials Regulation: 2019 and beyond

Life sciences report welcomed by the HRA

Our three new

Introduction from Teresa Allen, HRA Interim Chief Executive



Hello and welcome to the October edition of HRA Latest. It is my particular pleasure to introduce this issue as we have so many pieces of work coming to fruition currently.

Last week we published the [UK Policy Framework for Health and Social Care Research](#). Health and social care research has clear benefits, but it relies on people who give their money to fund and their time to participate.

It is therefore crucial that in return, research is planned, regulated and conducted in a way that inspires confidence – which we have recognised in the framework's 19 principles. Plus, [don't miss our short video](#) which introduces the framework.

Yesterday we published our [joint statement with the MHRA](#) advocating a proportionate approach to the application of Good Clinical Practice to researcher training. We have heard that sometimes researchers can get bogged down in



Health Research
Authority

Thank you!